Trade Basilea Pharma AG - BSLN CFD
Add to favourite- Summary
- Historical Data
Spread | 1.20 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.01431% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.007913% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | CHF | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | Switzerland | ||||||||
Commission on trade | 0% |
Prev. Close | 39.3 |
Open | 39.15 |
1-Year Change | -6.67% |
Day's Range | 38.65 - 39.8 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 26, 2024 | 38.95 | -0.20 | -0.51% | 39.15 | 39.80 | 38.65 |
Jul 25, 2024 | 39.40 | 0.45 | 1.16% | 38.95 | 39.40 | 37.75 |
Jul 24, 2024 | 38.55 | -0.35 | -0.90% | 38.90 | 39.15 | 37.90 |
Jul 23, 2024 | 38.95 | -0.95 | -2.38% | 39.90 | 40.05 | 37.90 |
Jul 22, 2024 | 39.90 | 0.15 | 0.38% | 39.75 | 40.15 | 38.95 |
Jul 19, 2024 | 39.85 | -1.05 | -2.57% | 40.90 | 40.90 | 39.85 |
Jul 18, 2024 | 40.60 | -0.90 | -2.17% | 41.50 | 41.85 | 40.30 |
Jul 17, 2024 | 41.65 | -0.25 | -0.60% | 41.90 | 42.95 | 41.30 |
Jul 16, 2024 | 41.85 | 2.30 | 5.82% | 39.55 | 42.60 | 39.05 |
Jul 15, 2024 | 39.95 | -1.00 | -2.44% | 40.95 | 41.00 | 39.25 |
Jul 12, 2024 | 41.10 | 0.55 | 1.36% | 40.55 | 41.20 | 40.30 |
Jul 11, 2024 | 40.65 | 1.05 | 2.65% | 39.60 | 40.65 | 39.25 |
Jul 10, 2024 | 39.35 | 0.25 | 0.64% | 39.10 | 39.40 | 38.05 |
Jul 9, 2024 | 39.30 | -0.20 | -0.51% | 39.50 | 39.70 | 38.65 |
Jul 8, 2024 | 39.20 | 0.20 | 0.51% | 39.00 | 40.20 | 38.95 |
Jul 5, 2024 | 39.70 | 0.95 | 2.45% | 38.75 | 39.80 | 38.50 |
Jul 4, 2024 | 38.85 | 0.35 | 0.91% | 38.50 | 38.85 | 37.90 |
Jul 3, 2024 | 38.15 | -0.55 | -1.42% | 38.70 | 38.70 | 38.15 |
Jul 2, 2024 | 38.55 | -0.20 | -0.52% | 38.75 | 38.75 | 37.70 |
Jul 1, 2024 | 38.55 | 0.15 | 0.39% | 38.40 | 39.20 | 38.25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Basilea Company profile
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
Hegenheimermattweg 167b
ALLSCHWIL
BASEL-LANDSCHAFT 4123
CH
News
![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ECB_0.png)
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024![](https://img.capital.com/imgs/articles/192x130x1/risk_2_1_optimized_450_1.png)
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024![](https://img.capital.com/imgs/articles/192x130x1/Stock-1-_1.png)
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ETF-1-_0.png)
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024![Lloyds share price forecast: An attractive dividend stock? Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/192x130x1/shutterstock_536730610_0.jpg)
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024![](https://img.capital.com/imgs/articles/192x130x1/RBNZ.png)
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com